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Abstract 
We investigated the cytotoxicity and biology of the novel broad-spectrum hydroxamic acid-based histone 
deacetylase inhibitor (HDACi), PCI-24781.  PCI-24781 was studied alone and combined with bortezomib 
in Hodgkin lymphoma (L428) and non-Hodgkin’s lymphoma cell lines (Ramos, HF1, SUDHL4). PCI-
24781 induced dose-dependent apoptosis that was associated with prominent G0/G1 arrest, decreased S-
phase, increased p21 protein expression, and production of reactive oxygen species (ROS).  Furthermore, 
PCI-24781-induced apoptosis was shown to be ROS- and caspase-dependent. Combined PCI-24781 and 
bortezomib exposure resulted in strong synergistic apoptosis in all cell lines (combination indices 0.19-0.6). 
Furthermore, compared to either agent alone, PCI-24781/bortezomib resulted in increased caspase cleavage, 
mitochondrial depolarization, and histone hyperacetylation. Microarray analyses showed that PCI-24781 
alone significantly downregulated several antioxidant genes, proteasome components, and NF-ĸB pathway 
genes, effects which were enhanced further with bortezomib. RT-PCR confirmed downregulation of NF-ĸB 
targets NF-ĸB1 (p105), c-Myc, and IĸB-kinase subunits, while gel-shift showed decreased NF-ĸB DNA-
binding activity. Taken together, these results suggest that increased oxidative stress and NF-ĸB inhibition, 
leading to caspase activation and apoptosis, are likely responsible for the activity of PCI-24781 as well as 
the observed synergy with bortezomib. These data indicate that PCI-24781 has potential therapeutic value 
in lymphoma as a single-agent and combined with bortezomib. 
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Introduction 
Lymphoid malignancies are caused in part by genetic and epigenetic deregulation of tumor suppressor genes.(1) 
The process of histone deacetylation is a well-characterized epigenetic modification.(2, 3) Histone deacetylases 
(HDAC) and histone acetylases are enzymes that have been shown to be aberrantly expressed or regulated in 
malignant tissues, resulting in inhibition of certain tumor suppressor genes, thereby allowing expression of the 
malignant phenotype. By inhibiting deacetylation of histones and allowing acetyl groups to remain on histones, 
HDAC inhibitors (HDACi) promote an open chromatin structure that allows gene transcription in relevant 
tumor suppressor genes that may favor tumor cell apoptosis.  
 
The biological effects of HDACi includes reversion of the transformed phenotype, inhibition of proliferation, 
cell cycle arrest, induction of differentiation, and apoptosis in tumor cell lines.(4-6) They have also been shown 
to generate reactive oxygen species (ROS) in solid tumor and leukemia cells (5, 7-9), which may contribute to 
the mechanism in these cell types. The novel HDACi, PCI-24781 (Pharmacyclics, Inc), is a broad spectrum 
phenyl hydroxamic acid-based, orally bioavailable compound currently in clinical trials for the treatment of 
neoplastic diseases.(10, 11)  It has activity in solid tumors including colorectal carcinoma in Phase I trials (12) 
and it is being evaluated in Phase II trials in a variety of malignancies, including lymphoma.  We evaluated the 
cytotoxicity and mechanism of action of HDACi PCI-24781, in Hodgkin lymphoma and non-Hodgkin’s 
lymphoma cell lines.   
 
Bortezomib is a proteasome inhibitor that received FDA approval in the United States for relapsed multiple 
myeloma and more recently for relapsed mantle cell lymphoma, where cell death has been associated with 
increased ROS.(13-15) Inhibition of proteasome activity by bortezomib results in stabilization of IĸBa with 
resultant NF-ĸB inhibition as well as stabilization of p53 and Bax, leading to apoptosis.  In addition, in vitro 
studies in solid tumors and hematologic malignancies (multiple myeloma and leukemia) have shown synergy 
when bortezomib and HDACi are combined.(16-20) There is however, little information on the activity and 
mechanism of this combination in lymphoma, with only one prior report in lymphoma (mantle cell histology) 
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where HDACi has been tested in combination with bortezomib.(18) We hypothesized that concomitant 
exposure of PCI-24781 and bortezomib might enhance apoptosis in other histologic subtypes of lymphoma 
(follicular lymphoma, diffuse large B-cell lymphoma, and Burkitt lymphoma) through ROS-related 
mechanisms.  We show here that the broad spectrum HDACi, PCI-24781, induced dose-dependent apoptosis in 
Hodgkin lymphoma and non-Hodgkin’s lymphoma cell lines, which was dependent on caspase and ROS 
production.  Further, it exhibited strong synergy with bortezomib, inducing ROS-dependent apoptosis in these 
cells. We analyzed the mechanisms of action of PCI-24781, bortezomib, and the combination by gene 
expression profiling in lymphoma cells and demonstrated that apoptosis occurred through interacting 
mechanisms including downregulation of oxidative stress response and several proteasome and NF-ĸB 
pathways, which were likely responsible for the observed synergy in these tumor cells. 
  
Materials and Methods 
Cell lines and reagents. 
The L428 Hodgkin lymphoma cell line and the Ramos (Burkitt lymphoma), HF1 (follicular lymphoma), and 
SUDHL4 (large B-cell lymphoma) non-Hodgkin’s lymphoma cell lines were cultured in RPMI1640 
(Invitrogen, Carlsbad, CA) with 10% fetal bovine serum (FBS), L-glutamine, and penicillin/streptomycin 
(Invitrogen, Carlsbad, CA). Cells were maintained at 37°C with 5% CO2. Bortezomib was provided by 
Millennium Pharmaceuticals (Cambridge, MA) and PCI-24781 was provided by Pharmacyclics Inc. 
(Sunnyvale, CA). Q-VD-OPh was used for pan-caspase inhibition (Calbiochem, San Diego CA), 6-carboxy-
2’7’-dichlorodihydrofluorscein (H2DCF-DA) for ROS, JC-1 and valinomycin, (Molecular Probes, Eugene, OR) 
for mitochondrial membrane potential, and catalase was obtained from Sigma-Aldrich (St. Louis, MO).  
Antibodies for caspase 8, caspase 9, caspase 3, acetyl histone H3 and H4, PARP (Cell Signaling, Beverly, MA), 
c-Myc (BD Pharmingen, San Diego, CA), cytochrome C, and p21 (Santa Cruz Biotech, Santa Cruz, CA) were 
used to study cell death pathways. GAPDH (Millipore Corporation, Temecula, CA) was used as a loading 
control for Western blotting. Secondary antibodies included horseradish peroxidase conjugated anti-rabbit and 
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anti-mouse immunoglobulin antibodies (Santa Cruz Biotech). AnnexinV-fluorescein isothiocyanate (annexinV-
FITC) detection kit (Biosource-Invitrogen, Camarillo, CA) was used to measure apoptosis. 
 
Quantification of apoptosis. 
Cell viability was examined morphologically after staining with trypan blue and by analysis of apoptosis using 
fluorescence activated cell sorting (FACS) after staining with annexinV-FITC and propidium iodide (PI). In 
brief, 1x106 cells were washed with phosphate buffered saline (PBS) and then labeled with annexinV-FITC /PI 
in the binding buffer according to manufacturer’s protocol. Fluorescent signals of FITC and PI were detected at 
518nm and 620nm, respectively, on a Beckman Coulter FACS instrument (Fullerton, CA). The data were 
analyzed with Flow Jo software (Tree Star, Ashland, OR). For each analysis 20,000 events were recorded. 
 
Measurement of ROS.  
Intracellular ROS concentration was determined by using cell permeable dyes as described previously.(21, 22) 
In brief, cells were washed with PBS and re-suspended in 1ml of RPMI containing 5μM H2DCF-DA and 
incubated at 37°C for 30 minutes in the dark. ROS were measured by oxidation of H2DCFDA to DCF. 
Fluorescence intensity was read by flow cytometry on the FL1 channel. 
 
Western blot analysis. 
Cells were centrifuged, washed with cold PBS, and lysed on ice for 30 minutes in lysis buffer containing 
protease and phosphatase inhibitors. Protein concentrations were determined with the Bio-Rad protein assay kit 
(Bio-Rad, Hercules,CA). Total protein (50μg) was electrophoresed on 12% SDS polyacrylamide gels and bands 
were visualized by chemiluminescence (Amersham Biosciences, Buckinghamshire, United Kingdom).  
 
Measurement of mitochondrial membrane potential (MMP). 
MMP was measured by flow cytometry using JC-1 staining.  Cells were washed with Hank’s buffered salt 
solution (HBBS) and incubated with 4 μg/ml JC-1 dye in HBSS for 15 minutes at 37oC in an incubator. Cells 
were washed with HBSS and immediately subjected to flow cytometric analysis. 
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Cell cycle analysis. 
Distinct phases of the cell cycle were distinguished by PI flow cytometry. Cells were washed in ice cold PBS, 
fixed in 70% ethanol, and stained for 30 minutes at 37°C with PI (50μg/ml PI in hypotonic sodium citrate 
solution containing 50μg/ml RNase) followed by flow cytometric analysis. The percentage of cells in G1, S, 
and G2/M phases were determined using the cell cycle analysis program Modfit LT (Verity Software, Topsham, 
ME).  
 
Protein extracts and electrophoretic mobility shift assay (EMSA). 
EMSA was performed using a gel-shift kit from Panomics (Fremont, CA). In brief, cellular extracts were 
prepared as described earlier and protein concentrations were determined using Bio-Rad’s protein assay reagent. 
The cellular extracts were then incubated with a biotin labeled NF-ĸB probe for 30 minutes at 15oC. The 
extracts were electrophoresed on a 6% polyacrylamide gel and transferred to a Hybond nylon membrane (Pall 
Corporation, Ann Arbor, MI). The membrane was blocked for 15 minutes in blocking buffer followed by 15 
min incubation with streptavidin-HRP antibody in the blocking buffer. Membranes were washed three times, 
developed using the detection kit and visualized using hyperfilm ECL (Amersham Biosciences, 
Buckinghamshire, United Kingdom).  
 
Real time polymerase chain reaction (RT- PCR) analysis.  
Taqman Gene Expression Assays for selected genes were obtained from Applied Biosystems Inc. (Foster City, 
CA). One-step RT-PCR was carried out in triplicate on 25ng of total RNA from each sample on an ABI PRISM 
7300 instrument according to the manufacturer’s standard protocols. The mRNA levels for each gene were 
normalized to the amount of RNA in the well as measured in parallel using Ribogreen (Molecular Probes, 
Eugene, OR). The treated samples were then normalized to the vehicle control at that time point.   
 
Microarray analysis.  
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The RNA expression profile was analyzed on custom Codelink oligonucleotide arrays (GE Biosciences, 
Piscataway, NJ), each containing 1857 gene probes, representing cellular cancer-related pathways, selected 
from the Codelink Human Genome arrays used in previous work.(11, 23) cRNA probes were prepared from the 
total RNA isolated from treated and control cells, and hybridized to the arrays using standard protocols 
(Codelink Protocol v2.1). Arrays were hybridized for 18 hours at 37°C, washed and detected with 
Strepatavidin-Alexa 647. They were scanned with a GenePix 4000B scanner (Molecular Devices, Sunnyvale, 
CA) and the images were processed with Codelink 4.0 Batch Processing software. The data were then analyzed 
in Genespring (Agilent Inc., Santa Clara, CA); only genes passing quality filters (“G”) and p-value cutoff of 
0.05 were used in the analyses.  
 
Statistics.  
For all apoptosis experiments (annexinV/PI and MMP), values represent the mean from three independent 
studies done in triplicate. Differences in groups were assessed by student t test and were considered statistically 
significant at p<0.05, <0.01, and <0.001. For the experiments combining bortezomib and PCI-24781, synergy 
was determined using isobologram analysis based on the method of Chou and Talay using the Calcusyn 
(Biosoft, Ferguson,MO) software program.(24) This method is based on the equation: 
CI=(D)1/(Dx)1+(D)2/(Dx)2, where D1 and D2 are doses of drug 1 and drug 2 that have x effect when used in 
combination, and (Dx)1 and (Dx)2 are the doses of drug 1 and drug 2 that have the same x effect when used 
alone.  
 
Results 
PCI-24781 induced apoptosis in Hodgkin lymphoma and non-Hodgkin’s lymphoma cell lines.   
The lymphoma cell lines were exposed to 0.5µM to 2µM PCI-24781 for 48 hours. PCI-24781 induced apoptosis 
in all cell lines in a dose-dependent manner (Figure 1A). The IC50 of PCI-24781 was 0.5µM for Ramos, 0.8 µM 
for SUDHL4, 0.9µM for HF1, and 1.4µM for L428. Apoptosis was time-dependent, with increasing cell death 
from 24 through 72 hours (data not shown).  Several reports have indicated that HDACi causes increased ROS 
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levels.(5, 7-9)  A four-fold increase in ROS was seen in Ramos and L428 cells following 24 hour exposure of 
PCI-24781 (Figure 1B). Similar ROS production was also demonstrated in SUDHL4 and HF1 cells following 
PCI-24781 exposure (data not shown). 
 
Bortezomib causes apoptosis and is synergistic with PCI-24781.  
Dose-dependent apoptosis was seen in all lymphoma cell lines following 48-hour exposure with increasing 
concentrations of bortezomib (Figure 2A). The IC50 for bortezomib was 20nM for L428 and 10nM for all three 
non-Hodgkin’s lymphoma cell lines. We next investigated whether apoptosis induced by bortezomib was 
associated with ROS production. As shown in Figure 2B, treatment of cells with bortezomib resulted in over 
10-fold increase in ROS in a dose-dependent manner in Ramos and L428 cells.  
 
At 48 hours, all cell lines exhibited a significant increase in apoptosis with the combination of PCI-24781 and 
bortezomib as shown in Figure 3A.  Combined treatment with 0.5μM PCI-24781 and 5nM bortezomib resulted 
in synergistic apoptosis in all three non-Hodgkin’s lymphoma cell lines, while the effects were additive or 
synergistic depending on concentrations of the drugs used in the L428 Hodgkin lymphoma cell line (Figure 
3A).  As shown by isobologram analyses (Figure 3 B), Ramos cells displayed stronger synergy (CI= 0.19 for 
0.5μM PCI-24781 and 5nM bortezomib) compared with other cell lines (CI= 0.3 to 0.6). In L428 cells, 
combination index values indicated synergy with 10nM bortezomib and 1μM PCI-24781 (CI=0.6), while 5nM 
bortezomib and 0.5μM PCI-24781 was additive (CI of 1.1; data not shown). 
 
An increase in ROS was also observed with combination PCI-24781/bortezomib and in Ramos as shown in 
Figure 3C. Cells were co-incubated with catalase, a free radical scavenger that degrades hydrogen peroxide. In 
Ramos (Figure 3D) and L428 (Figure 3E) cells, apoptosis induced by PCI-24781, bortezomib, and PCI-
24781/bortezomib combination were all abrogated in the presence of catalase, suggesting that the effects on 
apoptosis are in part ROS-mediated (Figure 3 D and 3 E).   
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PCI-24781/bortezomib-induced apoptosis is associated with early mitochondrial events (∆Ψm), caspase 
activation, and PARP cleavage. 
Mitochondria play a crucial role in the regulation of programmed cell death.(25)  The release of proteins from 
the inter-membrane space of mitochondria is a pivotal event in the initiation of the intrinsic cascade of 
apoptosis.(26)  Ramos cells showed 60% loss of MMP (∆Ψm), a signal of early apoptosis, with 5nM bortezomib 
and <20% with 2.5nM (Figure 4A); while PCI-24781 alone showed 25%-30% ∆Ψm (0.5μM-1μM). The 
combination of bortezomib (2.5nM) and PCI-24781 (0.5μM) resulted in over 80% ∆Ψm (P<0.01 combination vs 
single agents).  L428 cells showed minimal ∆Ψm following bortezomib treatment, while 50%-60% ∆Ψm was 
observed with PCI-24781 alone (Figure 4B). Higher concentrations were needed in L428, while the 
combination resulted in over 75% ∆Ψm.    
 
The involvement of caspases in PCI-24781 and bortezomib-induced apoptosis was assessed by detection of 
cleaved caspases and PARP by western blotting. As shown in Figure 4C, both agents induced caspase 8 and 9 
cleavage when used alone. However, the combination of bortezomib and PCI-24781 resulted in markedly 
increased cleaved caspase 8 and caspase 9 compared with either agent alone (Figure 4C). Cleavage of caspase 3 
and PARP was observed following treatment of cells with bortezomib or PCI-24781.  To assess the importance 
of caspase activation in bortezomib and/or PCI-24781-induced cell death, cells were co-incubated with the 
broad spectrum caspase inhibitor, Q-VD-OPh. Figure 4D shows that PCI-24781/bortezomib-indcued cell death 
in L428 and Ramos cells was in part caspase-dependent.   
 
Apoptosis is associated with cell cycle arrest and p21 upregulation. 
Dose-dependent G2/M arrest occurred following treatment of Ramos and L428 cells with bortezomib (Figure 
5A) that was accompanied by a decreased number of cells within the S and G1 phases. The treatment of cells 
with PCI-24781 resulted in G0/G1 arrest with a decrease in G2/M and S phase cell population (Figure 5B). The 
combination of bortezomib and PCI-24781 mimicked the effects of PCI-24781 alone. The biologic effects of 
HDACis are thought to be transduced at least in part by modifications of the acetylation state of histones. 
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Therefore, the effect of PCI-24781 and bortezomib on acetylation of histones was examined.  Hyperacetylation 
of histone H3 and H4 was observed following PCI-24781 treatment, as expected (Figure 5C).  Interestingly, 
bortezomib also provoked a small increase in the acetylation of histone H4, although to a much lesser extent.  
However, the combination of PCI-24781 and bortezomib resulted in a significant increase in histone acetylation 
(Figure 5C). The promoter of the transcription of the CDK inhibitor for p21 (CDKN1A) is regulated by histone 
acetylation status,(27) and up-regulation of p21 has been reported with HDAC inhibitors.(28, 29) We observed 
increased protein levels of p21 with PCI-24781, and more so with the combination (Figure 5D).   
 
Microarray analysis following PCI-24781 and/or bortezomib. 
Gene expression profiling using the pathway analysis chip revealed a subset of genes whose expression was 
altered in response to 0.25µM PCI-24781 and/or 3nM bortezomib treatment in Ramos cells. These 
concentrations were chosen since higher doses led to elevated cell death at the 24-hour time point. The Codelink 
oligonucleotide microarray used also included genes in other pathways of interest, including those previously 
shown to be affected by PCI-24781 treatment.(11) Statistical analyses of the data revealed a CV of 11.52% 
between four replicates, leading to a minimum detectable fold change of 1.3 according to the Codelink Analysis 
software (data not shown).  Selected genes meeting the p-value cutoff of 0.05 are shown in Table 1.  
 
The classical targets of both drugs were affected, including proteasome components and several HDACs 
(HDACs 1, 2, 7, 8) with bortezomib and PCI-24781 treatment, respectively. In addition to these, significant 
downregulation of genes in several pathways including cell cycle, proteasome, oxidative stress, and apoptosis 
were observed in response to PCI-24781 alone; these effects were enhanced in combination with bortezomib. In 
particular, it was observed that several anti-oxidant genes were downregulated by PCI-24781 alone and in 
combination with bortezomib, including thioredoxin-2 and thioredoxin reductase-2, heme oxygenase 2, 
catalase, glutathione reductase, and several glutathione reductases (Table 1). Some of these pathways have been 
previously linked with induction of apoptosis by these compounds. A marker for ROS induction, heme 
oxygenase 1 (HMOX-1), was also increased, but unlike HMOX-2, this gene may serve to facilitate apoptosis. It 
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is likely that transcriptional control of these anti-oxidant genes by PCI-24781 enhances the ROS accumulation 
and ROS-dependent apoptosis observed in the combination with bortezomib.    
 
Interestingly, PCI-24781 appeared to induce downregulation of the proteasome complex and many NF-ĸB 
target genes of both the canonical and alternative pathways (i.e., c-Myc, IĸB-kinase (IKK)-β, NFkB1, and Rel 
B) as well related chemokines and cytokines (including CCL3, CCL7, and IL-6).  Several of these genes were 
further downregulated by PCI-24781/bortezomib combination (c-Myc, myc-regulated genes, and the IKK 
catalytic subunits) supporting the mechanism of proteasome and NF-ĸB inhibition for synergy of this 
combination. Expression of the non-canonical (alternative) pathway components, NF-ĸB-inducing kinase (NIK) 
and the NF-ĸB subunit p52, were not affected by PCI-24781 and/or bortezomib (data not shown).  Changes 
were observed in other relevant pathways such as apoptosis, where pro-apoptosis genes including Fas and other 
TNFR family members (which activate the extrinsic pathway of apoptosis through caspase 8) were upregulated; 
pro-survival genes including c-FLIP and the IAP-repeat containing proteins survivin and apollon were 
decreased.  Large increases were also observed in the levels of CDK inhibitors, including p21, in agreement 
with the results shown in Figures 5D.   
 
Inhibition of NF-ĸB. 
To confirm the microarray analysis results, we measured the changes in mRNA and protein levels of several 
NF-ĸB targets by other methods. Accordingly, quantitative RT-PCR analysis of known NF-ĸB targets including 
NFĸB1 (p105, the precursor of the NF-ĸB subunit p50), c-Myc, and the two IKK catalytic subunits IKKα 
(IKK1) and IKKβ (IKK2) were measured. PCI-24781 alone markedly decreased NF-ĸB1, and to a lesser extent 
c-Myc and IKKβ (Figure 6A). Moreover, a notable decrease in all four of these transcripts was seen with PCI-
24781/bortezomib in combination.  Finally, we analyzed the NF-ĸB subunit p65 (Rel A) and c-Myc protein 
levels in response to bortezomib and PCI-24781 alone and in combination, by Western blotting (Figure 6B).  
NF-ĸB p65 protein levels did not change significantly, in agreement with the microarray results, whereas c-Myc 
protein was decreased by PCI-24781 alone and PCI-24781/bortezomib.  
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To further determine the effect that combined exposure of bortezomib and PCI-24781 has on NF-ĸB DNA 
binding activity, electrophoretic mobility shift analysis was performed (Figure 6C). A decrease in NF-ĸB 
activity was observed with 10nM-20nM bortezomib and 1µM-2µM PCI-24781 alone and in combination in 
Ramos and L428 cells. These findings support the concept that NF-ĸB signaling is a key component in the cell 
death pathways induced by PCI-24781 alone and in combination. 
 
Discussion 
In this work, we show that the novel broad spectrum hydroxamic acid-based HDACi, PCI-24781, induced dose-
dependent apoptosis in a Hodgkin lymphoma cell line and in several diverse non-Hodgkin’s lymphoma cell 
lines. PCI-24781 had an IC50 of <1µM in the non-Hodgkin’s lymphoma lines and <1.5µM for L428 cells, both 
clinically achievable concentrations.(10) Apoptosis occurred through ∆Ψm, ROS generation, and caspase 
activation in Hodgkin lymphoma and non-Hodgkin’s lymphoma cells. We observed that PCI-24781 alone 
induced a four-fold increase in ROS and furthermore, that apoptosis induced by PCI-24781 was ROS-
dependent, as cell death was abrogated when cells were pretreated with the anti-oxidant agent, catalase.  By 
contrast, in the only previously published study with HDACi combined with bortezomib in lymphoma (mantle 
cell lymphoma cells), it was observed that SAHA did not significantly induce ROS by itself, but did so robustly 
in combination with bortezomib(16). This may be attributable to differences in tumor type or the specific 
HDACi used.   
 
In this work, we also present the first microarray analysis of a HDACi/bortezomib combination response; we 
found that PCI-24781 downregulates the expression of many anti-oxidant genes including TXN2 and TNXRD2.  
The results of the pathway analysis presented here suggest that, in these lymphoma cell lines, the single-agent 
activity of PCI-24781 and the synergy with bortezomib in ROS-dependent cell death may be in part due to 
transcriptional regulation of the oxidative stress response by this HDACi.  It is important to note that 
combination studies are important, in part to overcome clinical resistance to single-agent therapy in disease 
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subsets where response is more limited, such as with bortezomib in diffuse large B-cell lymphoma(30) or 
bortezomib in Hodgkin lymphoma.(31) Thus, this work extends and offers mechanistic insights into the 
previous work in other tumor types regarding the ROS dependent synergy between HDACi and bortezomib. 
(16-20) 
 
The results presented here also delineate other molecular mechanisms that may contribute to the synergy of 
PCI-24781 and bortezomib.  Of note, it has been reported that the oxidative stress marker HMOX-1, which was 
upregulated in this study, can inhibit NF-ĸB activation by preventing its translocation into the nucleus and 
inhibiting the degradation of IĸB,(32, 33) and indeed that it may enhance bortezomib-induced cell death in 
leukemic cells.(34) The activation of NF-ĸB is known to play a critical role in the oncogenesis of lymphoid 
malignancies.(35, 36) In the present study, treatment with PCI-24781 alone led to significant downregulation of 
several components of the proteasome complex as well as many NF-ĸB target genes. The combination of PCI-
24781 and bortezomib resulted in further down-regulation of several NF-ĸB target genes including c-Myc (at 
protein and mRNA levels), myc-regulated genes, as well as the two catalytic subunits of IKK (IKKα and IKKβ) 
(Table 1 and Figure 6A).  More directly, the DNA-binding activity was also decreased following treatment of 
cells with these compounds as shown by the gel shift assay. The canonical NF-ĸB pathway appeared to more 
dominant in the lymphoma cells studied here as the PCI-24781/bortezomib combination primarily affected the 
p65/p50 complex through reduction of IKK activity and p50 expression (and its precursor, NF-ĸB1), which led 
to decreased nuclear translocation and decreased binding of NF-ĸB to its target promoters. HDACi that increase 
acetylation of proteins require an intact NF-ĸB signaling pathway to induce cell cycle arrest in human myeloid 
leukemia cells.(37) Interestingly, it has also been noted that several anti-oxidant genes are also regulated by NF-
ĸB, and that activation of the NF-ĸB pathway plays a vital role in the oxidative stress response of tumor cells 
(38) suggesting that ROS induction, downregulation of expression of thioredoxin-2 and other anti-oxidant genes 
and inhibition of NF-ĸB activation could all act synergistically in the activity of the PCI-24781/bortezomib 
combination in lymphoma.      
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The mode of apoptosis induction by the PCI-24781/bortezomib combination involved activation of both 
extrinsic (via caspase-8) and intrinsic (via caspase-9) caspase pathways.  Compared to either agent alone, PCI-
24781 and bortezomib together led to highly increased levels of cleaved caspase-8, caspase-9, caspase-3, and 
PARP.  The upregulation of several members of the TNF receptor superfamily may lead to the activation of the 
extrinsic pathway, while the activation of the intrinsic pathway via caspase-9 is consistent with the relatively 
early loss of mitochondrial potential ∆Ψm that is observed here.  Moreover, cell death was caspase-dependent as 
shown with pan-caspase inhibition, which inhibited apoptosis induced by PCI-24781 alone and combined with 
bortezomib.  It is also interesting that PCI-24781 decreased expression of c-FLIP and the pro-survival BIRC 
family members including survivin and apollon, which may all prevent cytochrome c release and caspase 
activation.  Further studies are needed to confirm the detailed mechanism of caspase activation in response to 
PCI-24781 and bortezomib in lymphoma.  
 
Finally, PCI-24781 mediated a prominent arrest of the lymphoma cells in the G0/G1 phase of the cell cycle, 
resulting in a marked decrease in S phase. This blockade of the cell cycle was accompanied by increased 
expression of p21, a cyclin-dependent kinase (CDK) inhibitor that plays an important role in cell cycle arrest 
during the G1 or G2 phase.(39) Prominent increases were also observed in other CDK inhibitors, including 
CDKN1B, CDKN1C, and CDKN2B (Table 1). Concordant decreases in many cyclins and CDKs, most 
prominently CDK4 and cyclin A2, likely contributed to the dramatic increase in G1 arrest and subsequent 
apoptosis in these lymphoma cell lines. As expected with an HDACi, there was also an accumulation of 
acetylated histone H3 and H4 with PCI-24781 treatment in these cells, which was synergistically increased by 
adding bortezomib; however, we and others have shown that histone acetylation is not directly correlated with 
sensitivity.(11, 40) It is likely however, that the enhanced accumulation of p21 is due to increased histone 
acetylation in these cells.(27) Further, histone acetylation (and its surrogate for compounds that inhibit HDAC6, 
tubulin acetylation) has proved to be an important and sensitive pharmacodynamic marker of HDAC activity in 
clinical studies, including the PCI-24781 studies currently underway.   
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In summary, our results show that the pan-HDACi, PCI-24781, when used alone exhibited dose-dependent 
apoptosis in a Hodgkin lymphoma cell line and several non-Hodgkin’s lymphoma cell lines.  Furthermore, the 
combination of PCI-24781 with bortezomib was strongly synergistic in these cells.  Apoptosis induced by PCI-
24781 alone and by the combination was ROS- and caspase-dependent.  Disruption of the cellular redox state 
with production of ROS and downregulation of oxidative stress response genes may represent an important 
mechanism underlying lymphoma cell death in response to PCI-24781 alone and combined with bortezomib. 
We showed that the NF-ĸB pathway, which is a major regulator of the oxidative stress response in cells, was 
inhibited by PCI-24781 alone and further when combined with bortezomib.  Finally, we showed that acetylation 
of histones and re-expression of p21 was greatly enhanced when bortezomib was added to PCI-24781. Thus, the 
combination of PCI-24781/bortezomib triggered cell death through interacting mechanisms including ROS 
generation, mitochondrial disruption, proteasome and NF-ĸB inhibition, cell cycle arrest, and caspase 
activation. Taken together our data suggest that PCI-24781 has potential therapeutic value in Hodgkin 
lymphoma and non-Hodgkin’s lymphoma as a single-agent and in combination with bortezomib.  
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Figure Legends  
Figure 1.   PCI-24781 dose-dependent apoptosis in lymphoma cell lines.   
A) Ramos (Burkitt lymphoma), HF1 (follicular lymphoma), SUDHL4 (diffuse large B cell lymphoma) and 
L428 (Hodgkin lymphoma) cell lines were cultured with increasing concentrations (0.5μM to 2.0μM) of PCI-
24781 for 48 hours. Percentage apoptosis was measured by annexinV/propidium iodide staining and analyzed 
by flow cytometry. B) Ramos and L428 cell lines were cultured with indicated concentrations of PCI-24781 for 
24 hours and ROS was measured. Peak shift to right denotes an increase in ROS production. Red line: no PCI-
24781, blue line: treated with PCI-24781. A shift towards the right indicates more ROS. *P<0.05, **P<0.01, 
and ***P<0.001 compared with control (RPMI).   Abbreviation: PCI, PCI-24781. 
 
Figure 2.  Effect of bortezomib on apoptosis in lymphoma cell lines. 
A) Bortezomib induced dose-dependent apoptosis in Ramos, HF1 SUDHL-4, and L-428. Cells were treated 
with indicated increasing concentrations of bortezomib, and at 48 hours, the percentage of apoptotic cells was 
determined by annexinV/propidium iodide staining and measured by flow cytometry. B) ROS levels were 
measured by flow cytometry in Ramos and L428 cells following incubation of cells with bortezomib for 6 hours 
followed by staining with H2DCF-DA. Red line: without treatment; blue line: treated with bortezomib. *P<0.05 
and **P<0.01 compared with control (RPMI). A shift towards the right indicates more ROS. 
 
Figure 3. Combined PCI-24781 with bortezomib induced synergistic apoptosis that was ROS-dependent.  
A) Co-treatment with bortezomib enhanced PCI-24781-related apoptosis. All cell lines were treated with 
varying concentrations of PCI-24781 (0.25μM to 1.0μM) and bortezomib (5nM to 10nM) either alone or in 
combination as indicated for 48 hours. Percentage of apoptotic cells was measured by flow cytometry after 
annexin V/propidium iodide (PI) staining. Isobolograms of Ramos (B) cell line treated with both PCI-24781 and 
bortezomib. Data points (blue circle, green plus, red x) indicate specific PCI-24781 and bortezomib 
concentrations at which apoptosis was 50%, 75% or 90% as indicated, after 48 hours. Lines connecting 
cytotoxic IC50, IC75, or IC90 for each drug signify a linear relationship between the drugs. Data points below each 
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respective straight colored line indicate synergistic cytotoxicity. C) ROS production in Ramos. Ramos cells 
were treated with the indicated concentrations of bortezomib and PCI-24781 for 16 hours followed by staining 
with H2DCF-DA analyzed by flow cytometry.  Red line: no drug treatment, blue line: with bortezomib, green 
line: with PCI-24781, and yellow line: bortezomib/PCI-24781 combined.  Apoptosis in Ramos (D) and L-428 
(E) was ROS-dependent. Catalase inhibited bortezomib and PCI-24781-induced apoptosis in Ramos and L428. 
Cell lines were treated with 4000 units of catalase for 2 hours following incubation with the 10nM bortezomib 
or 0.5μM (Ramos)/1.0μM (L428) PCI-24781 or combination bortezomib/PCI (Ramos 5nM bortezomib + 
0.5μM PCI and L428 with 10nM bortezomib + μM PCI) for 48 hours. The percentage of apoptotic cells was 
determined by annexinV/PI staining followed by flow cytometric analysis. PCI, PCI-24781; Bort, bortezomib.   
 
Figure 4.  ∆Ψm and caspase-dependent apoptosis with PCI-24781 and/or bortezomib. 
A) Ramos and B) L428 cells were treated with indicated concentrations of bortezomib and PCI-24781 for 24 
hours. The percentage of cells exhibiting loss of mitochondrial membrane potential (∆Ψm) was determined by 
JC-1 staining followed by flow cytometric analysis. P< 0.01 for PCI/bortezomib combinations vs single agents 
in Ramos.  C) Western blot analysis of cleaved caspases 3, 9, 8, and PARP activation in Ramos and L428 cells. 
Cells were treated with the indicated concentrations of bortezomib or PCI-24781 for 24 hours. D) The pan-
caspase inhibitor, Q-VD-OPh, inhibited bortezomib/PCI-24781-induced apoptosis in Ramos and L428 cells. 
Ramos and L428 cells were treated with combined bortezomib/PCI-24781 (5nM bortezomib and 0.5μM PCI-
24781 in Ramos and 10nM bortezomib and 1μM PCI-24781 in L428). For 48 hours alone (control) or with 4-
hour pretreatment with 50μM Q-VD-OPh. Apoptotic cells were detected by annexinV/propidium iodide 
staining and measured by flow cytometry. PCI, PCI-24781; Bort, bortezomib. MMP, mitochondrial membrane 
potential; QVD, Q-VD-OPh. 
 
Figure 5. Bortezomib and PCI-24781 cell cycle arrest and histone acetylation.   
A) Ramos and B) L428 cells were treated with the indicated concentrations of bortezomib or PCI-24781 and the 
combination for 24 hours and then stained with annexinV/propidium iodide and their cell cycle profiles were 
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examined. C) Western blot showing histone hyperacetylation and P21 upregualtion (D).  Cells were treated with 
5 nM (Ramos) or 10 nM (L428) of bortezomib and 0.5μ M (Ramos) or 1.0 μM(L428)  of PCI-24781 for 16 
hours. (D)The level of acetyl histone H3/H4 and p21 protein was measured using antibody as described in the 
Methods. GAPDH was used as internal control for all Western blots. PCI, PCI-24781; Bort, bortezomib.  
 
Figure 6. Effect of PCI-24781 and/or bortezomib on NFκB mRNA and protein and downstream targets.   
A) NF-ĸB1 (p105), c-Myc, IKKα, and IKKβ mRNAs were quantified by RT-PCR. Ramos cells were treated 
with the indicated concentrations of bortezomib and PCI-24781 for 24 hours. B) Western blot of c-Myc and NF-
ĸB p65 (RelA) protein expression.  Ramos and L428 cells were treated with indicated concentrations of 
bortezomib and of PCI-24781 as single agents and in combination for 24 hours. C) DNA binding activity of 
NF-ĸB by electromobility shift assay (EMSA). Ramos and L428 cells were treated with the indicated 
concentrations of bortezomib and PCI-24781 for 24 hours. Whole cell lysates were analyzed for NF-ĸB DNA 
binding activity by EMSA. IKK, IĸB-kinase; PCI, PCI-24781; Bort, bortezomib. 
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Downregulated genes
Accn # Name PCI Bort Comb
Cell cycle related
NM_000075 cyclin-dependent kinase 4 (CDK4) 0.49 0.83 0.37
NM_001237 cyclin A2 (CCNA2) 0.43 0.87 0.37
NM_001950 E2F transcription factor 4, p107/p130-binding (E2F4) 0.48 0.79 0.40
NM_001951 E2F transcription factor 5, p130-binding (E2F5) 0.46 0.98 0.43
NM_003903 CDC16 cell division cycle 16 homolog (S cerevisiae) (CDC16) 0.61 0.78 0.43
NM_031966 cyclin B1 (CCNB1) 0.55 0.90 0.43
NM_001760 cyclin D3 (CCND3) 0.48 1.02 0.46
NM_001255 CDC20 cell division cycle 20 homolog (S cerevisiae) (CDC20) 0.61 0.82 0.46
NM_001262 cyclin-dependent kinase inhibitor 2C (p18, inhibits CDK4) (CDKN2C) 0.61 1.15 0.56
NM_001238 cyclin E1 (CCNE1) 0.56 1.05 0.60
NM_001239 cyclin H (CCNH) 0.74 0.90 0.64
NM_004701 cyclin B2 (CCNB2) 0.90 0.95 0.67
NM_001240 cyclin T1 (CCNT1) 0.67 1.16 0.71
NM_001761 cyclin F (CCNF) 0.77 0.93 0.74
NM_001258 cyclin-dependent kinase 3 (CDK3) 0.60 1.14 0.80
NM_004702 cyclin E2 (CCNE2) 0.76 1.40 0.82
NM_001759 cyclin D2 (CCND2) 0.85 0.87 0.86
Proteasome 
NM_017518 26S proteasome-associated UCH interacting protein 1 (UIP1) 0.36 0.79 0.29
NM_002811 proteasome 26S subunit, non-ATPase, 7 (PSMD7) 0.68 1.44 0.57
NM_005047 proteasome 26S subunit, non-ATPase, 5 (PSMD5) 0.61 1.04 0.70
NM_002812 proteasome 26S subunit, non-ATPase, 8 (PSMD8) 0.60 1.13 0.70
NM_002794 proteasome subunit, beta type, 2 (PSMB2) 0.75 1.26 0.83
NM_002790 proteasome subunit, alpha type, 5 (PSMA5) 0.74 1.43 0.92
Oxidative Stress
NM_006440 thioredoxin reductase 2 (TXNRD2) 0.36 0.83 0.24
NM_145177 dehydrogenase/reductase (SDR family) X-linked (DHRSX) 0.37 0.87 0.40
NM_012473 thioredoxin 2 (TXN2) 0.60 0.94 0.53
NM_145792 microsomal glutathione S-transferase 1 (MGST1) 0.66 0.83 0.54
NM_002134 heme oxygenase (decycling) 2 (HMOX2) 0.66 0.89 0.57
NM_012331 methionine sulfoxide reductase A (MSRA) 0.74 0.86 0.72
NM_000637 glutathione reductase (GSR) 0.61 1.46 0.80
NM_001752 catalase (CAT) 0.93 0.72 0.83
NM_147149 glutathione S-transferase M4 (GSTM4) 0.89 0.92 0.87
NM_182743 thioredoxin reductase 1 (TXNRD1) 0.81 1.69 0.98
HDACs & Histones
NM_016596 histone deacetylase 7A (HDAC7A) 0.35 1.06 0.31
NM_004964 histone deacetylase 1 (HDAC1) 0.74 0.89 0.55
NM_018486 histone deacetylase 8 (HDAC8) 0.76 1.02 0.64
NM_001527 histone deacetylase 2 (HDAC2) 0.94 0.97 0.87
NF-kB target genes
BC022556 myc target 1 (MYCT1) 0.12 0.92 0.08
NM_001556 IkB kinase beta (IKBKB) 0.60 1.13 0.32
NM_032778 MYC induced nuclear antigen (MINA) 0.40 0.87 0.33
NM_002983 chemokine (C-C motif) ligand 3 (CCL3) 0.46 0.85 0.42
NM_003998 NFkB p105 (NFKB1) 0.47 1.19 0.43
NM_002467 v-myc viral oncogene homolog (MYC) 0.80 0.95 0.67
NM_006273 chemokine (C-C motif) ligand 7 (CCL7) 0.51 0.61 0.69
NM_006509 Rel B, NFkB subunit (RELB) 0.32 1.27 0.72
NM_014002 IkB kinase epsilon (IKBKE) 0.59 0.88 0.76
NM_000600 interleukin 6 (interferon, beta 2) (IL6) 0.84 1.28 0.81
NM_002503 IkB beta (NFKBIB) 0.80 1.22 0.82
BC033522 Rel A, NFkB p65 subunit 0.92 1.04 0.85
Apoptosis 
NM_001168 baculoviral IAP repeat-containing 5 (survivin) (BIRC5) 0.56 0.83 0.54
NM_003879 CASP8 and FADD-like apoptosis regulator (CFLAR)(c-FLIP) 0.60 1.03 0.56
NM_016252 baculoviral IAP repeat-containing 6 (apollon) (BIRC6) 0.75 1.10 0.72
0.25uM PCI/3nM Bort 
Table 1.   Selected genes from microarray analysis following 24-hour treatment with PCI-24781, 
bortezomib, or the combination in Ramos cells.*  
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Upregulated genes
Accn # Name PCI Bort Comb
Apoptosis & TNFR related 
NM_000177 gelsolin (GSN) 6.99 1.04 7.56
NM_032974 caspase 10, apoptosis-related cysteine protease (CASP10) 7.99 0.81 6.16
NM_006573 tumor necrosis factor (ligand) superfamily, member 13b (TNFSF13B) 3.59 1.91 3.38
NM_016639 tumor necrosis factor receptor superfamily, member 12A (TNFRSF12A) 2.02 0.79 2.44
NM_018647 tumor necrosis factor receptor superfamily, member 19 (TNFRSF19) -0.11 1.85 2.23
NM_003842 tumor necrosis factor receptor superfamily, member 10b (TNFRSF10B) 2.61 1.15 2.22
NM_014417 BCL2 binding component 3 (BBC3)(PUMA) 0.95 1.69 1.85
NM_138621 BCL2-like 11 (apoptosis facilitator) (BCL2L11) 1.43 0.94 1.79
NM_000043 Fas (TNFRSF6) (FAS) 1.72 1.46 1.73
NM_006290 tumor necrosis factor, alpha-induced protein 3 (TNFAIP3) 1.35 0.95 1.69
NM_003300 TNF receptor-associated factor 3 (TRAF3) 2.80 0.78 1.62
NM_000594 tumor necrosis factor (TNF superfamily, member 2) (TNF) 0.99 0.94 1.31
Cell Cycle Inhibitors
NM_000389 cyclin-dependent kinase inhibitor 1A (p21, Cip1) (CDKN1A) 25.87 0.92 28.45
NM_000076 cyclin-dependent kinase inhibitor 1C (p57, Kip2) (CDKN1C) 6.21 0.46 16.18
L36844 p15INK4B CDK inhibitory protein (CDKN2B) 5.26 2.54 4.49
NM_004064 cyclin-dependent kinase inhibitor 1B (p27, Kip1) (CDKN1B) 4.34 2.15 3.51
Cytoskeletal 
NM_178012 tubulin, beta 2B (TUBB2B) 14.66 0.87 16.45
BC056264 histone 1, H2bg (HIST1H2BF) 6.42 1.17 5.65
NM_021052 histone 1, H2ae (HIST1H2AE) 2.23 0.91 3.76
NM_021065 histone 1, H2ad (HIST1H2AD) 1.47 0.69 2.69
NM_003543 histone 1, H4h (HIST1H4H) 1.01 1.20 1.88
NM_001015053 histone deacetylase 5 (HDAC5) 1.22 1.09 1.71
NM_003509 histone 1, H2ai (HIST1H2AI) 1.12 0.80 1.45
NM_003516 histone 2, H2aa (HIST2H2AA) 1.13 1.00 1.41
NM_003528 histone 2, H2be (HIST2H2BE) 2.11 0.84 1.23
Oxidative Stress
NM_002738 protein kinase C, beta 1 (PRKCB1) 14.00 0.86 11.85
NM_002133 heme oxygenase (decycling) 1 (HMOX1) 6.52 1.82 7.53
NM_004417 dual specificity phosphatase 1 (DUSP1) 3.49 0.67 5.54
NM_005346 heat shock 70kDa protein 1B (HSPA1B) 2.23 3.74 5.27
Other
NM_002206 integrin, alpha 7 (ITGA7) 15.21 1.47 15.01
NM_002228 v-jun sarcoma virus 17 oncogene homolog (JUN) 4.06 0.94 12.14
NM_000584 interleukin 8 (IL8) 3.18 1.88 6.41
NM_000582 osteopontin, early T-lymphocyte activation 1 (SPP1) 3.67 0.82 5.07
NM_004862 lipopolysaccharide-induced TNF factor (LITAF) 2.26 1.20 2.08
0.25uM PCI/3nM Bort 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Changes are expressed as ratios of treated to control cell levels.   
 
Abbreviations: PCI, PCI-24781; Bort, bortezomib; comb, combination of PCI-24781 and  
bortezomib (0.25µM and 3nM, respectively). 
 
 
 






